Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ITCI.NASDAQ

Intracellular Th (ITCI NASDAQ) stock market data APIs

$81.16 0.77(1%) as of July 26, 2024
Price chart is built with Anychart

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intracellular Th Financial Data Overview

80.39
81.16
-
82
79.43
45.5-84.89
8 535 M
106 M
514 M
-0.16
1.007
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ITCI',
Type: 'Common Stock',
Name: 'Intracellular Th',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0026ZFZC4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1567514',
EmployerIdNumber: '36-4742850',
FiscalYearEnd: 'December',
IPODate: '2014-01-07',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Intracellular Th Fundamental Data is available in our Financial Data APIs

  • Net Revenue 514 M
  • EBITDA -131 415 000
  • Earnings Per Share -1.16
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Intracellular Th Earnings via APIs

  • Latest Release 2024-05-07
  • EPS/Forecast -0.32

Get Intracellular Th End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Intracellular Th latest news via APIs

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Inc. NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization ...

Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long

With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) future prospects. Intra-Cellular Therapies, Inc., a biopha...
Do you have any questions?
support@eodhistoricaldata.com